

**UNITED STATES OF AMERICA  
FEDERAL TRADE COMMISSION  
OFFICE OF ADMINISTRATIVE LAW JUDGES**

In the Matter of	)	
	)	
DYNAMIC HEALTH OF FLORIDA, LLC,	)	
CHHABRA GROUP, LLC,	)	DOCKET NO. 9317
DBS LABORATORIES, LLC,	)	
VINEET K. CHHABRA, a/k/a VINCENT K. CHHABRA, and	)	PUBLIC DOCUMENT
JONATHAN BARASH,	)	
Respondents.	)	

To: The Honorable Stephen J. McGuire  
Chief Administrative Law Judge

**COMPLAINT COUNSEL’S MOTION TO STRIKE THE FIRST THROUGH FIFTH  
AFFIRMATIVE DEFENSES ASSERTED IN RESPONDENTS’ ANSWER**

**I. INTRODUCTION**

Complaint Counsel respectfully move to strike the first through fifth affirmative defenses asserted in the Answer filed by Respondents Dynamic Health of Florida, LLC, Chhabra Group, LLC, and Vineet K. Chhabra, a/k/a Vincent K. Chhabra (“Respondents”) on July 23, 2004.<sup>1</sup> Those defenses should be stricken because they inject irrelevant or immaterial issues, assert defenses that are insufficient as a matter of law, and/or would prejudice Complaint Counsel by threatening an undue broadening of the issues. In support hereof, the following is respectfully submitted.

---

<sup>1</sup> This motion is timely. Excluding the time during which this case was stayed, only nine (9) business days have elapsed since the filing of Respondents’ Answer.

## II. LEGAL STANDARD FOR MOTIONS TO STRIKE

Although the Federal Trade Commission's Rules of Practice are silent on the subject of motions to strike affirmative defenses, the Commission has held that motions to strike may be filed and granted under the appropriate circumstances. *See Warner-Lambert Co.*, 82 F.T.C. 749 (1973); *Kroger Co.*, 1977 FTC Lexis 70 (Oct. 18, 1977) (Huyn, ALJ). "A motion to strike portions of an answer is a long established practice in FTC proceedings and well comports with the important objectives of economy and efficiency of administrative adjudications." *Kroger Co.*, 1977 FTC Lexis 70, \*1. By striking defenses, the Administrative Law Judge can exclude immaterial issues that threaten to expand discovery, to delay the proceedings, or to lead to irrelevant evidence at hearing. *See Warner-Lambert Co.*, 82 F.T.C. at 750 (upholding ALJ decision striking defenses).

The relevant federal rule and cases thereunder provide important guidance on this issue. The rule, Fed. R. Civ. P. 12(f), states that "[u]pon motion made by a party . . . the court may order stricken from any pleading any insufficient defense or any redundant, immaterial, impertinent, or scandalous matter." A Rule 12(f) motion serves to "avoid the expenditure of time and money that must arise from litigating spurious issues by dispensing with those issues prior to trial." *Sony Pictures Entertainment, Inc. v. Fireworks Entertainment Group, Inc.*, 156 F. Supp. 2d 1148, 1154 (C.D. Cal. 2001), quoting *Bureerong v. Uvawas*, 922 F. Supp. 1450, 1478 (C.D. Cal. 1986); see *Heller Financial, Inc., v. Midwehy Powder Co., Inc.*, 883 F.2d 1286 (7<sup>th</sup> Cir. 1989) (motions to strike appropriate to remove unnecessary clutter from the case). A defense is properly stricken if it is insufficient as a matter of law. *EEOC. v. First Nat'l Bank of Jackson*, 614 F.2d 1004 (5<sup>th</sup> Cir. 1980); *FTC v. Hang-Up Art Enterprises, Inc.*, 1995 U.S. Dist. LEXIS

21444, at \*8 (C.D. Cal. 1995). A defense that might confuse the issues in the case and would not, under the facts alleged, constitute a valid defense to the action can and should be deleted. *FDIC v. Main Hurdman*, 655 F. Supp. 259 (E.D. Cal. 1987). The affirmative defenses discussed below are legally insufficient, irrelevant to the ultimate question of violation under the FTC Act, or would lead to unnecessary and burdensome discovery. Accordingly, they should be stricken.

### III. LEGAL ARGUMENT

#### A. **This court should strike the defense that the challenged representations constitute protected commercial speech.**

Respondents' first affirmative defense is that "[T]he representations relating to Pedia Loss and Fabulously Feminine cited by the FTC qualify as protected commercial speech under the First Amendment to the Federal Constitution." (Respondents' Answer, "First Defense"). This defense is without any legal basis. Respondents agree that their internet and magazine advertising constitute commercial speech. It is well-established that commercial speech receives protection under the First Amendment only if it concerns lawful activity and is not misleading. *Central Hudson Gas & Elec. Corp. v. Public Service Comm. of New York*, 447 U.S. 557, 563, 564 (1980); see *Zauderer v. Office of Disciplinary Counsel*, 471 U.S. 626, 638 (1985) ("The States and the Federal Government are free to prevent the dissemination of commercial speech that is false, deceptive or misleading.") (citation omitted). Thus, under *Central Hudson*, if the Respondents' representations about Pedia Loss or Fabulously Feminine communicate false or misleading messages to consumers, they have no constitutional protection.

The complaint alleges that Respondents' advertising claims were false or misleading, in violation of the FTC Act. The issue of whether the challenged representations are deceptive is

one that will ultimately be decided by this court. Regardless of the court's finding on the issue of deception, Respondents' commercial speech rights are not infringed by this proceeding. If the Court finds that the Respondents' advertising claims are false or misleading, then there is no First Amendment violation because the First Amendment does not protect false or misleading commercial speech and an order prohibiting such speech is an appropriate remedy. If the Court finds that the Respondents' advertising claims are not false or misleading, then there still is no First Amendment violation because no restrictions will be imposed on the Respondents' future marketing statements.

Accordingly, Complaint Counsel requests that the court strike the defense that Respondents' advertising claims qualify as protected commercial speech under the First Amendment. *See, e.g., Metagenics, Inc.*, 1995 FTC LEXIS 2, \*2 (1995) (ALJ Parker) (striking affirmative defense that the proposed order would violate respondents' commercial free speech rights).

**B. This court should strike the defense that the remedy is overbroad under *Thompson v. Western States Medical Center*.**

Respondents assert in their second affirmative defense that the complaint must be rejected:

because the application of the Federal Trade Commission Act advocated by the FTC in this case places greater restrictions than necessary on commercial speech, and as a result the theory of liability relied upon by the FTC is barred pursuant to the decision of the Supreme Court of the United States in *Thompson v. Western States Medical Center*, 535 U.S. 357 (2002).

(Respondents' Answer, "Second Defense"). Respondents' assertion that the application of the FTC Act in this case places greater restrictions than necessary on commercial speech is

insufficient as a matter of law. In fact, the order proposed in this case would require only that Respondents possess prior substantiation for certain claims made in their advertising. As discussed below, it is well settled that the FTC's requirement of prior substantiation does not infringe constitutionally protected speech.

As a preliminary matter, Respondents' reliance on *Thompson v. Western States Medical Center* is misplaced given the factual differences between the remedies at issue. In *Thompson*, the Food and Drug Administration banned pharmacies from advertising, truthful or not, for particular "compounded" drugs. The Supreme Court, relying on *Central Hudson*, found that the advertising ban was more extensive than necessary to serve the particular governmental interests. 535 U.S. at 578. By contrast, the proposed order in this case does not consist of a wholesale prohibition on advertising. Instead, it requires prior substantiation for certain advertising claims in order to prevent deception.

Notably, the Commission's advertising substantiation requirements have withstood repeated First Amendment challenges in the circuit courts. In *Sears, Roebuck & Co. v. FTC*, 676 F.2d 385, 399-400 (9<sup>th</sup> Cir. 1982), *Sears* challenged an FTC order requiring that it have substantiation for its claims prior to disseminating them. *Sears* argued that this prior substantiation requirement amounted to an unconstitutional prior restraint of protected speech or that the order's breadth impermissibly chilled its First Amendment rights. The Ninth Circuit rejected these arguments, stating: "The Commission may require prior reasonable substantiation of product performance claims after finding violations of the [FTC] Act, without offending the first amendment." *Id.* Twenty years later, the Seventh Circuit reached a similar result, rejecting the argument that substantiation provisions in a cease and desist order violated the First

Amendment. *Kraft, Inc. v. FTC*, 970 F.2d 311, 326 (7<sup>th</sup> Cir. 1992), *cert. denied*, 507 U.S. 909 (1993); *see also Bristol-Myers Co. v. FTC*, 738 F.2d 554, 562 (2d Cir. 1984), *cert. denied*, 469 U.S. 1189 (1985) (“Nor is the prior substantiation doctrine as applied here in violation of the First Amendment.”); *Jay Norris, Inc. v. FTC*, 598 F.2d 1244, 1251-52 (2d Cir. 1979), *cert. denied*, 444 U.S. 980 (1979) (“because the FTC here imposes the requirements of prior substantiation as a reasonable remedy for past violations of the Act, there is no constitutional prior restraint of petitioners’ protected speech.”). Accordingly, Complaint Counsel requests the court to strike this defense. *FTC v. A. Glenn Braswell*, Case No. CV 03-3700DT (PJWx) (C.D. Cal.), at p. 20 (granting motion to strike First Amendment defense, noting that substantiation requirements have been upheld by numerous circuits) (attached).

**C. The court should strike the defense that the claims are permissible under the Dietary Supplement Health and Education Act of 1994 (“DSHEA”).**

Respondents assert in their third affirmative defense that:

The Complaint must be rejected because Congress clearly did not intend for the FTC to have authority to penalize advertising statements when the statements in question would qualify as entirely permissible structure/function label claims under the Dietary Supplement Health and Education Act.

(Respondents’ Answer, “Third Defense”). Without citing any authority, Respondents argue that the FTC is somehow barred from challenging claims subject to the Dietary Supplement Health and Education Act of 1994 (“DSHEA”). This defense is irrelevant, and should be stricken. It serves no purpose but to create a distraction from the fundamental question of whether Respondents’ actions are in violation of the FTC Act.

DSHEA amended the Federal Food, Drug, and Cosmetic Act to adopt certain provisions

regarding the labeling of dietary supplements. Specifically,

[S]ection 403(r)(6) of the act (21 U.S.C. 341(r)(6)), added by the DSHEA, allows dietary supplement labeling to bear a statement that "describes the role of a nutrient or dietary ingredient intended to affect the structure or function in humans" or that "characterizes the documented mechanism by which a nutrient or dietary ingredient acts to maintain such structure or function." These types of claims are generally referred to as "structure/function claims."

FDA, Regulations on Statements Made for Dietary Supplements Concerning the Effect of the Product on the Structure or Function of the Body, 63 Fed. Reg. 23624 (Apr. 29, 1998)

(introduction). The FTC complaint alleges that Respondents' advertising claims were false or misleading in violation of the FTC Act. Whether or not Respondents' claims are consistent with DSHEA has no bearing on the legality of Respondents' claims under Section 5 of the FTC Act.<sup>2</sup>

In *Horizon Corp.*, the Commission rejected a respondent's argument that the Department of Housing and Urban development had exclusive jurisdiction over land sales practices, noting,

The fact that some of [the provisions of the Interstate Land Sales Act provided to a division of HUD] review authority which is similar to the authority exercised by the FTC under Section 5 cannot be read as an expression of Congressional intent to grant exclusive jurisdiction. The FTC shares authority over various advertising and sales practices with several other agencies including the Consumer Product Safety Commission, the Food and Drug Administration and the Justice Department. Yet, despite these instances of overlapping agency authority, the FTC can be and is considered the agency with the foremost authority and expertise in the area of unfair and deceptive trade practices."

*Horizon Corp.*, 97 FTC 464, 862 (1981). Subsequently, the D.C. Circuit rejected the argument

---

<sup>2</sup> Moreover, there is no evidence that Respondents' claims are permissible under DSHEA. That statute requires that structure/function claims on dietary supplement labels be supported by "substantiation that such statement is truthful and not misleading." DSHEA, § 403 (r)(6)(B). 21 U.S.C. § 343 (r)(6)(B)(2004).

that the FTC should be barred from regulatory authority over drug advertising while FDA conducted a review of drug safety, stating, “the cases recognize that ours is an age of overlapping and concurring regulatory jurisdiction.” *Thompson Medical Co. v. Federal Trade Commission*, 791 F.2d 189, 192 (D.C. Cir. 1986), *cert. denied*, 479 U.S. 1086 (1987).

Respondents have offered only their own conjecture in support of the proposition that Congress, in enacting DSHEA’s requirements regarding dietary supplement labeling, intended to divest the FTC of its concurrent jurisdiction over the product category. The legislation contains no statement to this effect.<sup>3</sup> See DSHEA, 108 Stat. 4325, P.L. 103-417 (S. 784)<sup>4</sup>; 103 S. Rpt. 410 (Oct. 8, 1994).<sup>5</sup> Allowing this affirmative defense to stand would unnecessarily complicate and delay this proceeding. It would thrust the parties and this court into unnecessary and burdensome discovery that could entail, for example, depositions of FDA officials and review of FDA regulations. As a result, a similar defense has been struck in a prior Part III case. See, *Metagenics, Inc.*, 1995 FTC LEXIS 2 (1995) (ALJ Parker) (striking defense that claims were acceptable under FDA regulations). Thus, because the defense will serve to confuse the issues and would not, under the facts alleged, constitute a valid defense to the action, this court should strike it. See *Main Hurdman*, 655 F. Supp. at 263.

---

<sup>3</sup> Subsequent to enactment of DSHEA, the FTC issued a business guidance document to instruct advertisers of dietary supplements about the need for compliance with the FTC Act. Dietary Supplements, An Advertising Guide for Industry, available online at <http://www.ftc.gov/bcp/online/pubs/buspubs/dietsupp.htm#Application>. There would be no need for such guidance if DSHEA had divested the FTC of jurisdiction over dietary supplement ads.

<sup>4</sup> Available in Lexis through “Lexsee.”

<sup>5</sup> Available in Lexis through the LEGIS library, CMTRPT file, search “103 S. Rpt. 410.”



**D. The court should strike the defense of estoppel.**

Respondents' fourth affirmative defense asserts that:

The Complaint must be rejected because official statements regarding the relationship between dietary supplement structure/function claims and the substantiation requirements of the Federal Trade Commission made by the Food & Drug Administration in the Federal Register on January 6, 2000, 65 FR 1000 at 1012, clearly require that the defense of entrapment by estoppel be applied against the Federal Trade Commission in this case.

(Respondents' Answer, "Fourth Defense"). This assertion suggests that certain statements by the FDA made in the Federal Register in some way amounted to entrapment, warranting a defense of estoppel. This assertion is without any legal or factual basis, and should be stricken.

The Federal Register page cited by Respondents contains a statement that "FDA agrees that some structure/function claims that are acceptable under DSHEA may be difficult to substantiate." 65 Fed. Reg. 1000 at 1012 (2000). It goes on, however, to state that "Difficulty in substantiating [structure/function claims] does not alter the terms of the statute. Manufacturers are responsible for determining whether claims for their products can be appropriately substantiated. . . ." *Id.* Thus, nothing in the cited material would support an estoppel argument.

In any event, the defense is immaterial. The law is unequivocal that the equitable doctrines of estoppel is not applicable as a defense to an action brought by the government in the public interest. *Horizon Corp.*, 97 F.T.C. 464, 860 (1981); *National Dietary Research, Inc.*, 1994 FTC Lexis 47 (1994) (Parker, ALJ) (striking affirmative defense of estoppel, waiver, and laches). Accordingly, Respondents' Fourth Affirmative Defense should be stricken because it is insufficient as a matter of law. *FTC v. American Microtel, Inc.*, 1992 U.S. Dist. Lexis 11046 (D. Nev. 1992) (striking defenses of laches and estoppel).


**E. The court should strike the defense that the complaint fails on the merits.**

In their fifth affirmative defense, Respondents assert that the complaint must be rejected because “it fails on the merits.” (Respondents’ Answer, “Fifth Defense”). This defense does not conform to the specificity requirements of Commission Rule 3.12(b)(1)(i), which requires a concise statement of the facts constituting each ground of defense. Respondents’ bald and conclusory assertion that the complaint “fails on the merits” provides absolutely no hint as to the nature of the alleged deficiencies in the Commission’s complaint. For this reason alone, it should be stricken. *See FTC v. Bay Area Business Council, Inc.*, 2003 U.S. Dist. Lexis (N.D. Ill.) (striking defense that complaint fails to state a claim upon which relief can be granted for failure to comply with pleading requirements contained in the Federal Rules).

**IV. CONCLUSION**

For the foregoing reasons, Complaint Counsel respectfully request that the court strike the first through fifth affirmative defenses asserted in Respondents’ Answer.

Respectfully submitted,



---

Janet M. Evans (202) 326-2125  
Sydney M. Knight (202) 326-2162  
Division of Advertising Practices  
FEDERAL TRADE COMMISSION  
600 Pennsylvania Avenue, N.W.  
Mail drop NJ-3212  
Washington, D.C. 20580  
[jevans@ftc.gov](mailto:jevans@ftc.gov)  
[sknight@ftc.gov](mailto:sknight@ftc.gov)  
Fax: (202) 326-3259

**UNITED STATES OF AMERICA  
FEDERAL TRADE COMMISSION**

---

In the Matter of )

DYNAMIC HEALTH OF FLORIDA, LLC )

CHHABRA GROUP, LLC )

DBS LABORATORIES, LLC )

VINEET K. CHHABRA aka VINCENT K. CHHABRA, and )

JONATHAN BARASH, )

Respondents. )

---

Docket No. 9317

**[Proposed] ORDER REGARDING COMPLAINT COUNSEL'S MOTION TO STRIKE  
AFFIRMATIVE DEFENSES**

The Court has considered the "COMPLAINT COUNSEL'S MOTION TO STRIKE RESPONDENTS' AFFIRMATIVE DEFENSES," filed October 21, 2004. Complaint counsel has demonstrated that the Affirmative Defenses should be stricken because they inject irrelevant or immaterial issues, assert defenses that are insufficient as a matter of law, and/or would prejudice Complaint Counsel by threatening an undue broadening of the issues. Accordingly, it is hereby ruled that Complaint Counsel's Motion to Strike is GRANTED.

Ordered:

---

Stephen J. McGuire  
Chief Administrative Law Judge

Date:

**CERTIFICATE OF SERVICE**

I hereby certify that I have this 20th day of October, 2004 filed and served the attached **COMPLAINT COUNSEL'S MOTION TO STRIKE THE FIRST THROUGH FIFTH AFFIRMATIVE DEFENSES ASSERTED IN RESPONDENTS' ANSWER and [Proposed] ORDER REGARDING COMPLAINT COUNSEL'S MOTION TO STRIKE AFFIRMATIVE DEFENSES** upon the following as set forth below:

(1) the original and one (1) paper copy filed by hand delivery and one electronic copy via email to:

Donald S. Clark, Secretary  
Federal Trade Commission  
600 Pennsylvania Ave., N.W., Room H-159  
Washington, D.C. 20580  
E-mail: [secretary@ftc.gov](mailto:secretary@ftc.gov)


(2) two (2) paper copies served by hand delivery to:

The Honorable Stephen J. McGuire  
Chief Administrative Law Judge  
600 Pennsylvania Ave., N.W. Room H-112  
Washington, D.C. 20580

(3) one (1) electronic copy via email and one (1) paper copy via first class mail to:

Max Kravitz, Esq.  
Kravitz & Kravitz LLC  
145 East Rich Street  
Columbus, OH 43215  
[mkravitz@kravitzlawnet.com](mailto:mkravitz@kravitzlawnet.com)  
614-464-2000  
fax: 614-464-2002

I further certify that the electronic copy sent to the Secretary of the Commission is a true and correct copy of the paper original, and that a paper copy with an original signature is being filed with the Secretary of the Commission on the same day by other means.

  
\_\_\_\_\_  
Sydney Knight

ENTERED  
CLERK, U.S. DISTRICT COURT  
NOV 13 2003  
CENTRAL DISTRICT OF CALIFORNIA  
BY *WLB* DEPUTY

FILED  
CLERK, U.S. DISTRICT COURT  
NOV 10 2003  
CENTRAL DISTRICT OF CALIFORNIA  
BY DEPUTY

STAMPED

Priority   
Send   
Enter   
Closed   
JS-5/JS-6   
JS-2/JS-3   
Scan Only

THIS CONSTITUTES NOTICE OF ENTRY  
AS REQUIRED BY FRCP, RULE 77(d).

UNITED STATES DISTRICT COURT  
CENTRAL DISTRICT OF CALIFORNIA

FEDERAL TRADE COMMISSION,  
Plaintiff,

vs.

A. GLENN BRASWELL, JOL  
MANAGEMENT CO., G.B. DATA  
SYSTEMS, INC., GERO VITA  
INTERNATIONAL, INC.,  
THERACEUTICALS, INC., AND RON  
TEPPER

Defendants.

CASE NO. CV 03-3700DT (PJWx)

ORDER DENYING IN PART AND  
GRANTING IN PART PLAINTIFF  
FEDERAL TRADE COMMISSION'S  
MOTION TO STRIKE VARIOUS  
AFFIRMATIVE DEFENSES OF  
DEFENDANTS A. GLENN  
BRASWELL, JOL MANAGEMENT  
CO., G.B. DATA SYSTEMS, INC.,  
THERACEUTICALS, INC.

**I. Background**

**A. Factual Summary**

This action is brought by Plaintiff, the Federal Trade Commission ("FTC" or "Commission"), which is an independent agency of the United States Government created by statute. 15 U.S.C. §§ 41-58. The Commission brings this action against Defendants A. Glenn Braswell, ("Braswell"), JOL Management Co., ("JOL"), G.B. Data Systems, Inc., Gero Vita International, Inc., ("GVI"),

42

1 Theraceuticals, Inc., (“Theraceuticals”), and Ron Tepper (“Tepper”) - all of which  
2 are hereinafter collectively referred to as the “Braswell Common Enterprise.”

3 The Commission brings this action under Section 13(b) of the Federal  
4 Trade Commission Act (“FTC Act”), to secure a permanent injunction, restitution,  
5 disgorgement, and other equitable relief against the Braswell Common Enterprise  
6 for engaging in deceptive acts or practices and false advertising in connection with  
7 the advertising, marketing, and sale of products purporting to treat, prevent, and or  
8 cure such conditions as respiratory illnesses, diabetes, dementia, obesity, and  
9 impotence, in violation of Sections 5(a) and 12 of the FTC Act, 15 U.S.C. §§ 45(a)  
10 and 52. See Complaint for Permanent Injunction and Other Equitable Relief  
11 (hereinafter “Complaint”) at 1-2.

12 The Commission alleges the following facts in its Complaint:

13 For over twenty-five years, Braswell has marketed dietary  
14 supplements and other health-related products through a frequently changing  
15 group of interrelated companies. See Complaint at ¶ 5. Defendants Braswell,  
16 JOL, G.B. Data Systems, GVI, Theraceuticals, and Tepper operate a common  
17 business enterprise. Id. at ¶ 11. They share and have shared officers, employees,  
18 and office locations; have commingled funds; and are commonly controlled and  
19 have participated in a common scheme to engage in deceptive acts and practices,  
20 making them jointly and severally liable for said acts and practices. Id.

21 The Braswell Common Enterprise is one of the largest direct  
22 marketers of dietary supplements and other health-related products in the United  
23 States, with total sales since 1998 exceeding \$798 million. See Complaint at ¶ 13.  
24 The Braswell Common Enterprise uses direct mail solicitations to generate  
25 business. See Complaint at ¶ 14. It purchases or rents consumer names and  
26  
27  
28

1 addresses from brokers, targeting persons aged 40 to 60, and mails advertising to  
2 these consumers. Id.

3 New and repeat purchasers receive multi-page advertisements that  
4 describe various medical conditions and detail various remedies - often  
5 purportedly based on "scientific breakthroughs" or "long lost but newly  
6 discovered" formulas. Id. Defendants claim that their products will cure, treat, or  
7 alleviate these conditions in glossy, multi-page brochures that typically feature  
8 "expert" medical or scientific endorsers, consumer testimonials, and frequent  
9 references to "scientific" evidence that purport to substantiate the efficacy and  
10 benefits of the products. Id.

11 Purchasers also receive a "subscription" to the *Journal of Longevity*,  
12 which appears to be a legitimate medical journal with scientific articles written by  
13 medical professionals but which is, in fact, promotional advertising prepared and  
14 disseminated by Defendants. Id. Consumers can purchase the advertised products  
15 via mail order, telephone, or electronically on Defendants' website, [www.gvi.com](http://www.gvi.com).  
16 Id.

17 Defendants' advertisements contain a return address in Toronto,  
18 Canada, to which consumers send their orders via mail. See Complaint at ¶ 15. In  
19 fact, Defendants have no employees in Canada and all such mail orders are sent  
20 from the Canadian mail drop address to Defendants' offices in the United States  
21 for fulfillment. Id.

22 Among the products that Defendants have advertised, labeled, offered  
23 for sale, sold and distributed in recent years are: Lung Support Formula, Gero Vita  
24 G.H.3, and Testorex, all marketed since at least 1998; ChitoPlex, marketed since at  
25 least 1999; AntiBetic Pancreas Tonic, marketed since at least 2000; and  
26 Therapeutics GH3 Romanian Youth Formula, marketed since at least 2001. See

1 Complaint at ¶ 16. Like their other products, Defendants advertise and offer these  
2 products for sale through direct mail advertising, including the *Journal of*  
3 *Longevity*, and through their website, [www.giv.com](http://www.giv.com). *Id.*

SCANNED

4 In its Complaint, the Commission details the specific claims made for  
5 each product, indicating the symptoms that each product cures or alleviates, and  
6 includes testimonials from consumers indicating their endorsement for the  
7 products. See generally, Complaint at 6-31.

8 Defendants have represented, either expressly or by implication, that  
9 Lung Support cures or significantly alleviates certain lung diseases and respiratory  
10 problems, reverses existing lung damage in persons with emphysema, prevents  
11 breathing problems for otherwise healthy persons, and is clinically proven to  
12 eliminate or cure allergies, asthma, colds, and other illnesses and conditions. See  
13 Complaint at ¶ 29. The representations made with regards to Lung Support are  
14 false or were not substantiated at the time the representations were made,  
15 constituting a deceptive practice, and the making of false advertisements in  
16 violation of Sections 5(a) and 12 of the FTC Act, 15 U.S.C. §§ 45(a) and 52. See  
17 Complaint at ¶ 30.

18 Defendants have represented, either expressly or by implication, that  
19 AntiBetic can cure Type I and Type II diabetes, is an effective or superior  
20 alternative to insulin or other medications for the treatment of diabetes, and is  
21 clinically proven to regenerate or repair the pancreatic beta cells that produce  
22 insulin and to lower blood sugar levels in persons with diabetes. See Complaint at  
23 ¶ 31. The representations made with regards to AntiBetic are false or were not  
24 substantiated at the time the representations were made, constituting a deceptive  
25 practice, and the making of false advertisements in violation of Sections 5(a) and  
26 12 of the FTC Act, 15 U.S.C. §§ 45(a) and 52. See Complaint at ¶ 32.



SCANNED

1 Defendants have represented, either expressly or by implication, that  
2 G.H.3 is clinically proven to reverse and prevent age-related memory loss,  
3 dementia, and Alzheimer's disease, and can increase life spans by 29%. See  
4 Complaint at ¶ 33. The representations made with regards to G.H.3 are false or  
5 were not substantiated at the time the representations were made, constituting a  
6 deceptive practice, and the making of false advertisements in violation of Sections  
7 5(a) and 12 of the FTC Act, 15 U.S.C. §§ 45(a) and 52. See Complaint at ¶ 34.

8 Defendants have represented, either expressly or by implication, that  
9 ChitoPlex enables consumers to lose substantial weight without the need for a  
10 restricted calorie diet or exercise, reverse obesity, and is proven to cause weight  
11 loss based on a 1994 double-blind, placebo-controlled chitosan study conducted in  
12 Finland that resulted in chitosan subjects losing an average of 15 pounds in four  
13 weeks while consuming their normal diet. See Complaint at ¶ 35. The  
14 representations made with regards to ChitoPlex are false or were not substantiated  
15 at the time the representations were made, constituting a deceptive practice, and  
16 the making of false advertisements in violation of Sections 5(a) and 12 of the FTC  
17 Act, 15 U.S.C. §§ 45(a) and 52. See Complaint at ¶ 36.

18 ~~The Defendants have represented, either expressly or by implication,~~  
19 ~~that Testex is effective in treating impotence or erectile dysfunction in 62-95%~~  
20 ~~of users, and is safe with no harmful side effects. See Complaint at ¶ 37. The~~  
21 ~~representations made with regards to Testex are false or were not substantiated~~  
22 ~~at the time the representations were made, constituting a deceptive practice, and~~  
23 ~~the making of false advertisements in violation of Sections 5(a) and 12 of the FTC~~  
24 ~~Act, 15 U.S.C. §§ 45(a) and 52. See Complaint at ¶ 34.~~

25 Through the use of the statements contained in advertisements,  
26 Defendants have represented, directly or by implication that all Gero Vita products  
27

1 have been scientifically tested and proven to be effective, when in truth and in  
2 fact, they have not been. See Complaint at ¶¶ 39-40. Therefore, the making of  
3 these representations constitutes a deceptive practice, and the making of false  
4 advertisements in violation of Sections 5(a) and 12 of the FTC Act, 15 U.S.C. §§  
5 45(a) and 52. Id. at ¶ 40.

6 Defendants have represented, expressly or by implications, that the  
7 *New Life Nutrition* magazine is an independent publication and not paid  
8 commercial advertising, when in truth and in fact, the *New Life Nutrition*  
9 magazine is not an independent publication, and is paid commercial advertising  
10 written and disseminated by Defendants for the purpose of selling their products.  
11 See Complaint at ¶¶ 41-42. Therefore, the making of these representations  
12 constitutes a deceptive practice, and the making of false advertisements in  
13 violation of Sections 5(a) and 12 of the FTC Act, 15 U.S.C. §§ 45(a) and 52. Id. at  
14 ¶ 42.

15 Defendants have represented, expressly or by implication, that the  
16 Council on Natural Nutrition is an independent organization that has expertise in  
17 the examination and evaluation of nutritional health products, and that the Council  
18 conferred its exclusive Golden Nutrition Award on three of Defendants' products,  
19 including G.H.3, and ChitoPlex, based upon its senior scientific editors'  
20 independent, objective, and valid examination and evaluation of thousands of  
21 nutritional health products, using procedures generally accepted by experts in the  
22 relevant fields to yield accurate and reliable results. See Complaint at ¶ 43.

23 In truth and in fact, the Council on Natural Nutrition is not an  
24 independent organization that has expertise in the examination or evaluation of  
25 nutritional health products, and it did not confer its exclusive Golden Nutrition  
26 Award on the Defendants' products, including G.H.3, and ChitoPlex, based upon  
27

1 its senior scientific editors' independent, objective, and valid examination and  
2 evaluation of thousands of nutritional health products, using procedures generally  
3 accepted by experts in the relevant fields to yield accurate and reliable results. See  
4 Complaint at ¶ 44. The Council on Natural Nutrition was established by  
5 Defendants and has been used by Defendants for the purpose of selling their  
6 products. Id.

7 In addition, the Council on Natural Nutrition does not have a staff of  
8 "senior scientific editors" with expertise in evaluating health-related products, and  
9 at least one of the "senior scientific editors" is or was an employee of Defendants  
10 with no scientific training in the examination or evaluation of nutritional health  
11 products. Id. The making of these representations constitutes a deceptive  
12 practice, and the making of false advertisements in violation of Sections 5(a) and  
13 12 of the FTC Act, 15 U.S.C. §§ 45(a) and 52. Id.

14 Defendants have represented, expressly or by implication, that Dr.  
15 Ronald Lawrence, Director of the Council on Natural Nutrition, has endorsed  
16 Defendants' products, including G.H 3 and ChitoPlex, based upon his  
17 independent, objective evaluation of the products. See Complaint at ¶ 45.  
18 Defendants have failed to disclose that Dr. Lawrence and the Council on Natural  
19 Nutrition have material connections to Defendants. Id. Among other things, Dr.  
20 Lawrence is a paid endorser of Defendants' products and is or was a member of  
21 Defendant G.B. Data Systems' Board of Directors. Id.

22 The Council on Natural Nutrition is or was an organization  
23 established by Defendants and is or was used for the purpose of advertising and  
24 promoting their products. Id. Therefore, the failure to disclose these facts, in light  
25 of the representations made, constitutes a deceptive practice, and the making of  
26  
27  
28

1 false advertisements in violation of Sections 5(a) and 12 of the FTC Act, 15  
2 U.S.C. §§ 45(a) and 52. Id.

3 Consumers throughout the United States have suffered and continue  
4 to suffer substantial monetary loss as a result of the Defendants' unlawful acts or  
5 practices. See Complaint at ¶ 46. In addition, Defendants have been unjustly  
6 enriched as a result of their unlawful practices. Id. Absent relief, Defendants are  
7 likely to continue to injure consumers, reap unjust enrichment, and harm the  
8 public interest. Id.

9 **B. Procedural Summary**

10 On May 27, 2003, the Commission filed its Complaint for Permanent  
11 Injunction and Other Equitable Relief in the United States District Court for the  
12 Central District of California against Defendants.<sup>1</sup>

13 On May 28, 2003, the Commission filed Pro Hac Vice applications  
14 on behalf of Theodore H. Hoppock, Jill F. Dash, Mamie Kresses, David P.  
15 Frankel, and Rosemary Rosso.

16 On June 17, 2003, the Commission and Defendant Tepper<sup>2</sup> filed a  
17 Stipulation to Extend Time to Respond to Complaint.

18  
19  
20  
21  
22

---

23 <sup>1</sup> The named Defendants in the Complaint include A. Glenn Braswell, JOL  
24 Management Co., G.B. Data Systems, Inc., Gero Vita International, Inc.,  
25 Therapeutics, Inc., and Ron Tepper.

26 <sup>2</sup> The stipulation was by and between Plaintiff Federal Trade Commission  
27 and Ron Tepper. The parties stipulated that the time in which Defendant Tepper  
28 could respond to the Complaint was extended for 27 days.

1 On July 14, 2003, Defendant Braswell<sup>3</sup> filed a Motion to Stay  
2 Proceeding Pending Resolution of Criminal Charges and a Memorandum of Points  
3 and Authorities in support thereof.

4 On July 14, 2003, Defendant Tepper filed a Motion to Dismiss  
5 Complaint.

6 On July 16, 2003, the Commission and Defendants filed a Joint  
7 Stipulation to Extend Time to File Answer and to File Rule 16(b) Scheduling  
8 Order.

9 On July 17, 2003, Defendants filed an Amended Motion to Stay  
10 Proceedings Pending Resolution of Criminal Charges and a Memorandum of  
11 Points and Authorities in support thereof.

12 August 4, 2003, Defendant Tepper filed a Joinder in Defendants'  
13 Motion to Stay Proceeding Pending Resolution of Criminal Charges.

14 On August 25, 2003, Defendants filed Pro Hac Vice applications on  
15 behalf of Christopher R. Cooper and Randall J. Turk.

16 On September 11, 2003, Defendant Braswell, JOL, G.B. Data  
17 Systems, GVI and Theraceuticals filed a Joinder in Defendant Tepper's Motion to  
18 Dismiss Complaint.

19 On September 15, 2003, a Non-Resident Attorney Application was  
20 filed by Mark Stancil on behalf of A. Glenn Braswell.

21 On September 15, 2003, this Court entered an Order Denying  
22 Defendant A. Glenn Braswell's Motion to Stay Proceeding Pending Resolution of  
23 Criminal Charges.

---

24  
25 <sup>3</sup> The Motion notes: "This motion is being filed on behalf of Mr. Braswell  
26 only. Were the motion to be granted, however, it would make little sense to have  
27 the case proceed solely against the corporate defendants. The corporate  
28 defendants therefore join this motion."

SCANNED

1 On September 15, 2003, this Court entered an Order Denying  
2 Defendant Ron Tepper's Motion to Dismiss Complaint Pursuant to Federal Rule  
3 of Civil Procedure 12(b)(1), 12(b)(6), 9(b) & 9(f).

4 On September 25, 2003, Defendant Tepper filed an Answer to  
5 Complaint and Affirmative Defenses. In the Answer, Defendant Tepper made a  
6 Demand for Trial by Jury.

7 On September 26, 2003, Defendant A. Glenn Braswell, JOL  
8 Management Co., G.B. Data Systems, Inc., and Theraceuticals, Inc. filed an  
9 Answer and Affirmative Defenses Memorandum.

10 On October 3, 2003, this Court filed an Order Setting Scheduling  
11 Conference for December 1, 2003.

12 On October 17, 2003, Plaintiff filed a Motion to Strike Various  
13 Affirmative Defenses of Defendants A. Glenn Braswell, JOL Management Co.,  
14 G.B. Data Systems, Inc., Theraceuticals, Inc., and Ron Tepper ("Motion to  
15 Strike"), which is before this Court.<sup>4</sup>

16  
17 **II. Discussion**

18 **A. Standard**

19 Federal Rule of Civil Procedure 12(f) provides that "[u]pon motion  
20 made by a party . . . the court may order stricken from any pleading any  
21 insufficient defense, or any redundant . . . matter." (FED.R.CIV.P. 12(f)). A Rule

22  
23 <sup>4</sup> The FTC's Motion to Strike requests that this Court strike eight  
24 affirmative defenses plus two additional statements raised in the Answer filed by  
25 A. Glenn Braswell, JOL Management Co., G.B. Data Systems, Inc., Gero Vita  
26 International, Inc. and Theraceuticals, Inc. In addition, in the same Motion to  
27 Strike, the FTC requests that this Court strike nine affirmative defenses plus two  
28 additional statements raised in Defendant Ron Tepper's Answer. (See Motion to  
Strike at 1.)

1 12(f) motion to strike is “proper when a defense is insufficient as a matter of law.”  
2 (See FTC v. Medicor, LLC, 2001 WL 765628, \*1 (C.D.Cal.) (citing Schwarzer,  
3 Tashima & Wagstaffe, *California Practice Guide: Federal Civil Procedure Before*  
4 *Trial* ¶ 9:378 (2001)). It is the moving party’s burden to establish the following:  
5 (1) the absence of questions of fact; (2) that any questions of law are beyond  
6 dispute; (3) that there is no set of circumstances under which the challenged  
7 defense could succeed; and (4) presentation of the defense would prejudice the  
8 moving party. (See Schwarzer, at ¶¶ 9:381, 9:375, 9:407.) Thus, a motion to  
9 strike will not be granted if the insufficiency of the defense is not clearly apparent,  
10 or if it raises factual issues that should be determined by a hearing on the merits.  
11 (See Medicor, 2001 WL 765628 at \*1 (citing 5A C. Wright & A. Miller, Federal  
12 Practice and Procedure (2d ed. 1990) § 1381 at 678)). The function of a 12(f)  
13 motion to strike is to avoid the expenditure of time and money that must arise  
14 from litigating spurious issues by dispensing with those issues prior to trial . . .”  
15 Id. (citing Sidney-Vinstein v. A.H. Robins Co., 697 F.2d 880, 885 (9th Cir. 1983)).

16  
17 **B. Analysis**

18 The FTC seeks to strike eight of ten affirmative defenses asserted by  
19 Defendants. (See Answer and Affirmative Defenses of Defendant A. Glenn  
20 Braswell, JOL Management Co., G.B. Data Systems, Inc., and Therapeutics, Inc.  
21 (“Answer”) at 13-14). This Court addresses each of these below. At the outset,  
22 though, this Court notes the high threshold involved in striking an affirmative  
23 defense. (See Standard, supra.) To a large extent, in seeking to strike certain  
24 affirmative defenses, the FTC is asking this Court to determine factual issues and  
25 the merits of the defenses and/or claims asserted. However, at this juncture of the  
26 litigation, this Court cannot do so. Nonetheless, it should also be noted that while

1 this Court may not strike the defense at this time, Defendants will still be required  
2 to ultimately prove the merits of the defense.

3  
4 **1. This Court Denies the FTC's Motion to Strike Defendants' First**  
5 **Affirmative Defense of Good Faith to the Extent it is Asserted**  
6 **Against the Granting of a Permanent Injunction**

7 The FTC argues that Defendants' affirmative defense of good faith  
8 must be stricken because "the law is well-established that good faith is not a  
9 defense to the FTC Act." (See Motion to Strike at 4.) This Court agrees that good  
10 faith may not be offered as an affirmative defense to a violation of section 5 of the  
11 FTC Act. However, to the extent that the affirmative defense is asserted *against*  
12 *the granting of a permanent injunction*, it is permitted.

13 A careful reading of the case law makes it clear that while good faith  
14 is not relevant to whether the actual violation of section 5 of the FTC Act  
15 occurred, it is relevant to the issue of whether a permanent injunction is  
16 appropriate. (See Medicor, 2001 WL 765628 at \*\*2-3; Hang-Ups, 1995 WL  
17 914179 at \*3). This is because the granting of a permanent injunction requires  
18 that "there exist some cognizable danger of recurrent violation." (See Hang-Ups,  
19 1995 WL 914179 at \*3 (citing United States v. W.T. Grant Co., 345 U.S. 629, 633  
20 (1953)). The determination of whether the alleged violations are likely to recur,  
21 requires the court to look at: (1) the deliberateness . . . of the present violation, and  
22 (2) the violator's past record." (See id. (citing Sears, Roebuck & Co. v. FTC,  
23 Id. 676 F.2d 385, 392 (9th Cir. 1982)). As the court in Hang-Ups noted, "good  
24 faith on the part of the defendant[s] could be determinative of the first factor and  
25 therefore preclude injunctive relief." (See Hang-Ups, 1995 WL 914179 at \*3.)



1 Since the FTC is seeking a permanent injunction against Defendants  
2 (see Complaint at 1-2), the issue of whether the wrongful acts were “deliberate” is  
3 indeed relevant to the issue of whether a permanent injunction is appropriate. (See  
4 Complaint at 1-2.) This Court declines the FTC’s invitation to ignore the Medicor  
5 and Hang-Ups decision and denies the FTC’s Motion to Strike Corporate  
6 Defendants’ good faith affirmative defense *to the extent it is asserted against the*  
7 *granting of a permanent injunction.*<sup>5</sup>  
8

9 **2. This Court Denies the FTC’s Motion to Strike Defendants’ Second**  
10 **Affirmative Defense of Laches.**

11 The FTC moves to strike Defendants’ laches affirmative defense  
12 because “it is well established that laches is not a defense to a civil suit to enforce  
13 a public right or to protect a public interest.” (See Motion to Strike at 4.) In  
14 response, Defendants argue that the law is, in fact, not well-settled, and that the  
15 laches defense requires a factual determination making it inappropriate to strike it  
16 at this juncture. (See Opposition at 8-9.)  
17  
18

---

19 <sup>5</sup> The FTC cites numerous cases that purportedly support the proposition  
20 that good faith is not a defense to violations of section 5 of the FTC Act.  
21 However, the FTC’s argument is not wholly persuasive for several reasons. First,  
22 while the FTC gives great weight to decisions from several other jurisdictions, it  
23 gives short shrift to two cases within this jurisdiction that expressly upheld the  
24 assertion of a good faith defense against an FTC complaint seeking permanent  
25 injunctive relief and individual liability (i.e. the Medicor and Hang-Ups  
26 decisions). Second, although the FTC suggests otherwise, the ultimate outcome of  
27 the Medicore case is irrelevant to whether the affirmative defense is sufficient to  
28 survive a motion to strike. Third, in support of its position, the FTC cites Hang-  
Ups; however, as both parties noted in their Oppositions, it is clear that the  
quotation used was taken *completely out of context*.

SCANNED

1 Traditionally, the doctrine of laches has not been available against the  
2 government in a suit by it to enforce a public right or protect a public interest.  
3 (See Hang-Ups 1995 WL 914179 at \*4 (quoting United States v. Ruby Co., 588  
4 F.2d 697, 705 n.10 (9th Cir. 1978)). However, laches “may be a defense against  
5 the government if ‘affirmative misconduct’ by the government is shown.” (Id.  
6 (quoting Ruby, 588 F.2d at 705 n.10)). The applicability of laches against the  
7 government is determined on a case-by-case basis. (See Hang-Ups, 1995 WL  
8 914179 at \*4 (noting that “[t]he facts of the case should decide whether there has  
9 been affirmative misconduct by the government such that laches might apply”);  
10 Occidental Life Ins. Co. of California v. E.E.O.C., 432 U.S. 355, 373 (1977)  
11 (determined on a case-by-case basis)).

12 Based on the above, the granting of the FTC’s Motion to Strike this  
13 affirmative defense under Fed.R.Civ.P. 12(f) is improper because (1) it is not  
14 beyond dispute whether the laches defense is applicable; (2) there would be a set  
15 of circumstances under which the laches defense could succeed; and (3) even if  
16 the laches defense does apply, a potential question of fact regarding the presence  
17 of “affirmative misconduct” by the government exists. In addition, while the FTC  
18 argues that Defendants have conceded that they do not intend to allege bad faith or  
19 improper purpose and that Defendants’ assertion that affirmative misconduct may  
20 be present is “nothing but bare bones conclusory allegations,” Defendants  
21 vigorously reject this assertion, and note that the FTC’s suggestion that  
22 Defendants have conceded the absence of affirmative misconduct in prior  
23 pleadings is “absurd.” (See Opposition at 9.) This further supports this Court’s  
24 decision not to strike Defendants’ affirmative defense of laches at this time.  
25  
26  
27  
28

1           **3. This Court Grants the FTC's Motion to Strike Defendants' Third**  
2           **Affirmative Defense of Failure to Exhaust Administrative**  
3           **Remedies**

4           The FTC argues that Defendants' third affirmative defense, failure to  
5 exhaust administrative remedies, must be stricken for several reasons. First, "[t]he  
6 plain reading of 13(b) of the FTC Act . . . makes clear that the Commission is not  
7 required to pursue its case administratively prior to invoking this Court's  
8 jurisdiction." (See Motion to Strike at 5.) Second, the FTC argues that the FTC's  
9 authority to bring Section 13 (b) actions directly in federal court has been  
10 examined and upheld by numerous courts. (*Id.*)

11           The right to bring Section 13(b) actions directly in federal court has  
12 indeed been examined and upheld by numerous district and appellate courts. (See  
13 Motion to Strike at 5 (citing *United States v. JS & S Group, Inc.*, 716 F.2d 451  
14 (7th Cir. 1983) (holding that the FTC may seek a permanent injunction in federal  
15 court . . . without having first instituted administrative proceedings))). This  
16 authority was restated in the Ninth Circuit in *FTC v. Pantron I Corp.*, where the  
17 court held that Section 13(b) "gives the federal courts broad authority to fashion  
18 appropriate remedies for violations of the [FTC] Act." (See *Pantron*, 33 F.3d  
19 1312, 1314-15 (9th Cir. 1994)). The language of the FTC Act states: "Whenever  
20 the Commission has reason to believe . . . that any person, partnership, or  
21 corporation is violating or is about to violate, any provision of law enforced by the  
22 Federal Trade Commission . . . the Commission may . . . bring suit in a district  
23 court of the United States to enjoin any such act or practice. (See 15 U.S.C. §  
24 53(b)(1) (2003)).

25           Contrary to Defendants' argument, there is no requirement in either  
26 Section 13(b) or Section 53(b) that administrative remedies be exhausted before  
27

the FTC is authorized to bring suit in a district court of the United States. Further, the lack of any case law to the contrary leads this Court to grant the FTC's Motion to Strike Defendants' affirmative defense of failure to exhaust administrative remedies.

**4. This Court Grants the FTC's Motion to Strike Defendants' Fourth Affirmative Defense of Statute of Limitations**

Defendants argue that the FTC's claims under Section 13(b) are subject to the three-year statute of limitations present in Section 19 of the FTC Act. (See Opposition at 10-11.) The gist of Defendants' argument is that since ancillary relief in the form of consumer relief is available under Section 13(b), claims under Section 13(b) must at least comply with the consumer relief provisions of Section 19, including the three-year statute of limitations. (See Opposition at 13-14.) In contrast, the FTC contends that, in addition to case law, the clear language of Section 19 precludes the application of the three-year statute of limitations to actions brought under Section 13(b). (See Motion to Strike at 7.)

Under Section 13(b), ancillary equitable relief, including rescission of contracts and monetary relief in the form of consumer redress and disgorgement for violations of the FTC Act is authorized. (See e.g., Pantron I Corp., 33 F.3d 1088 (9th Cir. 1994); FTC v. Silueta Dist., Inc., 1995 WL 215313, \*7 (N.D. Cal. 1995) (noting that the Ninth Circuit's interpretation of Section 13(b) allows federal courts to broadly apply their equitable powers)). Although Section 13(b) does not explicitly state or refer to any statute of limitations (see Motion to Strike at 7), several courts have held that "the three-year statute of limitations contained in Section 19 of the FTC Act is *not* applicable to Section 13(b) cases." (See FTC Minuteman Press, 53 F.Supp.2d 248 (E.D. N.Y. 1998); United States v. Building

1 Inspector of America, Inc., 894 F. Supp. 507, 514 (D. Mass. 1995)).<sup>6</sup> Section 19  
2 provides in relevant part: "Remedies in this section are in addition to, and not in  
3 lieu of, any other remedy or right of action provided by State or Federal law.  
4 *Nothing in this section shall be construed to affect any authority of the*  
5 *Commission under any other provision of law.*"

6 Based on the absence of language in Section 13(b) indicating the  
7 presence of a statute of limitations and the clear language in Section 19, this Court  
8 finds that the FTC's Motion to Strike Defendants' statute of limitations affirmative  
9 defense should be granted.

10  
11 **5. This Court Denies the FTC's Motion to Strike Defendants' Fifth**  
12 **Affirmative Defense of Offset/Setoff**

13 In seeking to strike the affirmative defense of offset/setoff, the FTC  
14 argues that the appropriate measure of equitable monetary relief pursuant to  
15 Section 13(b) of the FTC Act is the full amount lost by consumers without regard  
16 to Defendants' profits and with a deduction only for refunds already made. (See  
17 Motion to Strike at 8 (citing FTC v. Febre, 128 F.3d 530, 536 (7th Cir. 1997)).  
18 Defendants respond that "the FTC's objections to offset of monetary relief are  
19 premature and unsupported." (See Opposition at 15.) Moreover, Defendants  
20 argue that the determination of whether benefits received by consumers can be  
21 considered in determining relief is a factual matter. (Id. at 18.)

22 Based on the numerous cases cited by both parties in support of their  
23 respective positions, this Court finds that a determination as to the applicability of  
24

25  
26 <sup>6</sup> As the FTC notes in its Reply, "the Commission determined to pursue this  
27 case in federal court, pursuant to 13(b) rather than through . . . Section 19(a)(2) . .  
28 . a decision . . . within its sound discretion." (See Reply at 5 n.4.)

1 | this affirmative defense at this time is premature. In other words, the law that an  
 2 | offset/setoff is not allowed is not “beyond dispute.” In fact, while the FTC argues  
 3 | that *no* deductions are proper, the FTC’s own case law demonstrates that the types  
 4 | of “offset/setoff” sought by Defendants are frequently deducted from overall  
 5 | judgments. For example, in Medicor,<sup>7</sup> the court affirmed the \$16.6 million  
 6 | disgorgement judgment only after noting that the FTC “presented the declaration  
 7 | of an accountant indicating that *refunds, charge backs, and returns have been*  
 8 | *deducted*. (See Medicor, 217 F.Supp.2d at 1057-58 (emphasis added)). In FTC v.  
 9 | Amy Travel Serv. Inc.,<sup>8</sup> the court actually affirmed a reduction for consumers who  
 10 | received a benefit. (See Amy, 875 F.2d 564, 572 (7<sup>th</sup> Cir. 1989) (noting that “the  
 11 | magistrate correctly acknowledged the existence of satisfied customers in  
 12 | computing the amount of defendants’ liability—customers who actually took  
 13 | vacation trips were excluded when the magistrate computed the amount of  
 14 | restitution awarded”)). Finally, in FTC v. SlimAmerica, Inc., the court affirmed  
 15 | an \$8.4 million redress judgment and stated, “[t]he appropriate measure for redress  
 16 | is [the] aggregate amount paid by consumers, less *refunds* made by defendants.”  
 17 | (See SlimAmerica, 77 F.Supp.2d 1263, 1275-76 (S.D. Fla. 1999)).

18 |           Based on the above, it is clear that at least some types of deductions  
 19 | Defendants request have been permitted. This is not to say that this Court will  
 20 | allow them here. Rather, this Court must assess this issue in light of the particular  
 21 | facts of this case as compared to the facts of these other cases. Thus, this Court  
 22 | denies the FTC’s Motion to Dismiss Defendants’ offset/setoff affirmative defense.

---

25 |           <sup>7</sup> See Motion to Strike at 9.

26 |           <sup>8</sup> See FTC’s Motion to Strike at 9.

1           **6. This Court Grants the FTC's Motion to Strike Defendants' Sixth**  
2           **Affirmative Defense of First Amendment Violation**

3           Defendants incorporate the arguments explained in Defendant  
4           Tepper's Motion to Dismiss the Complaint and further assert that the FTC's  
5           theory "that a statement is false or misleading simply because the speaker lacked  
6           substantiation at the time the statement was made is unconstitutional." (See  
7           Opposition at 20.) In response, the FTC argues that this affirmative defense must  
8           be stricken. This Court agrees with the FTC.

9           First, this Court has already ruled that "the mere initiation of this  
10          lawsuit does not restrict in any way the [Defendant's] ability to engage in truthful,  
11          non-misleading speech . . . At this time, this Court finds that the Commission's  
12          allegations, if proven, will establish that Defendants have engaged in commercial  
13          speech that is either false or misleading, neither of which would result in the  
14          infringement of [Defendants'] First Amendment right of freedom of speech." (See  
15          Motion to Strike at 10 (citing Order Denying Defendant Ron Tepper's Motion to  
16          Dismiss Complaint Pursuant to Federal Rules of Civil Procedure 12(b)(1),  
17          12(b)(6), 9(b) & 9(f) at 19 (Sept. 15, 2003))). As such, This Court finds that  
18          Defendants' affirmative defense must be stricken because the issue has already  
19          been decided by this Court. (See FED.R.CIV.P. 12(f) (noting that "upon motion  
20          made by a party . . . the court may order stricken from any pleading any  
21          insufficient defense, or any redundant . . . matter"))).

22          Further, as the FTC argues, the FTC's advertising substantiation  
23          requirements have been upheld by numerous circuits, including the Ninth Circuit  
24          in Sears, Roebuck & Co. v. FTC, where the court rejected Sears' argument that its  
25          First Amendment rights had been violated. (See Sears, 676 F.2d 385, 399-400  
26          (9th Cir. 1982)). The court stated: "The Commission may require prior reasonable  
27  
28

SCANNED

1 substantiation of product performance claims after finding violations of the [FTC]  
2 Act, without offending the First Amendment.” (Id.) Thus, a violation of the First  
3 Amendment does not result from the mere initiation of a lawsuit.

4  
5 **7. This Court Denies the FTC’s Motion to Strike Defendants’**  
6 **Seventh Affirmative Defense of Waiver**

7 Defendants assert that assessing the scope of consumer harm is an  
8 issue that cannot be addressed until after “the evidence is in.” (See Opposition at  
9 22.) In other words, Defendants argue that there is a significant issue of fact that  
10 is unresolved at this stage of the pleadings, making it inappropriate to strike  
11 Defendants’ affirmative defense. In response, the FTC argues that if the FTC is  
12 able to prove that “consumers’ purchasing decisions were founded, in part, on  
13 false, deceptive or unsubstantiated claims, then such claims are clearly actionable  
14 under longstanding and well-established precedent, irrespective of whether  
15 consumers entered into contracts.” (See Motion to Strike at 12.) Again, based on  
16 the parties’ own contentions, it is clear that the determination before this Court is  
17 premature at the pleading stage.

18 The FTC Act may be violated if a defendant “induces the first contact  
19 through deception, even if the buyer later becomes fully informed before entering  
20 the contract.” (See Resort Rental Car Sys., Inc., 518 F.2d 962, 964 (9th Cir.  
21 1975)). Since the determination of whether a waiver is present hinges on a finding  
22 of deception, this question of fact requires this Court to deny the FTC’s Motion to  
23 Strike Defendants’ affirmative defense of waiver.





1 become apparent during discovery.” (See Answer at 14 (emphasis added)). This  
 2 Court agrees with the FTC that Defendants’ right, if any, to assert additional  
 3 affirmative defenses is governed by Fed. R. Civ. P. 15 and an appropriate request  
 4 to seek leave to amend the Answer to do so.

5           **10. To the Extent that the Relief Sought by the FTC is Limited to a**  
 6           **Permanent Injunction and Other Ancillary Relief Under Section**  
 7           **13(b), Defendants’ Request for a Jury Trial is Denied**

8           Defendants argue that they are entitled to a trial by jury because the  
 9 relief sought by the FTC is “so significant that it cannot fairly be said [to be] a  
 10 request for prospective injunctive relief.” (See Opposition at 25.) In response, the  
 11 FTC contends that Defendants have no right to a jury trial under Section 13(b)  
 12 because the relief sought is limited to “a permanent injunction and other equitable  
 13 ancillary relief derived from the Court’s authority to issue such a permanent  
 14 injunction, pursuant to Section 13(b) of the FTC Act.” (See Motion to Strike at 18  
 15 (citing FTC v. H.N. Singer, Inc., 1982 WL 1907 \*\*38-39 (N.D. Cal. 1982); Hang-  
 16 Ups, 1995 WL 914179 at \*3).

17           This Court agrees with the FTC that the cases cited by it make clear  
 18 that there is no right to a trial by jury in an action under Section 13(b) of the FTC  
 19 Act, where the monetary relief the FTC seeks is not punitive, but rather is ancillary  
 20 to the requested injunctive relief.<sup>10</sup> To the extent that Defendants believe such  
 21 monetary relief may become unlimited or punitive in nature, the FTC is bound by  
 22 its representations that it “would limit its request for monetary relief to the amount  
 23 paid by consumers, less any refunds,” and more importantly, it is bound by the  
 24 equitable nature of the relief sought.

---

25  
 26           <sup>10</sup> This Court also notes that Defendants have cited no case law in support  
 27 of their argument to the contrary.

1 **III. Conclusion**

2           Based on the foregoing, this Court **Denies** the FTC's Motion to Strike  
3 Defendants' **First, Second, Fifth and Seventh** affirmative defenses. This Court  
4 **Grants** the FTC's Motion to Strike as to Defendants' **Third, Fourth, Sixth, and**  
5 **Eighth** affirmative defenses. This Court finds that Defendants' ability to assert  
6 additional affirmative defenses is governed by FED.R.CIV.P. 15. This Court  
7 further finds that, to the extent that the relief sought by the FTC is limited to a  
8 permanent injunction and other ancillary relief under Section 13(b), Defendants'  
9 request for a jury trial is denied.

10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

IT IS SO ORDERED.

DATED: NOV 10 2003

**DICKRAN TEVRIZIAN**  
\_\_\_\_\_  
Dickran Tevrizian, Judge  
United States District Court